MORRISVILLE, N.C. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 . The company will host a conference call and webcast at 8:30 a.m.

MORRISVILLE, N.C. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022 , the Precedential Opinion Panel (POP) of the United States Patent and Trademark Office (USPTO) denied a request by United Therapeutics (UTC) to review the decision by

MORRISVILLE, N.C. , Oct. 17, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the CHEST 2022

District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patent All patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB) PTAB decision to invalidate all claims of ‘793 patent is not affected

MORRISVILLE, N.C. , Aug. 22, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 7,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022 .

MORRISVILLE, N.C. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 . The company will host a conference call and webcast at 8:30 a.m.

Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso ® per session Achieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into

MORRISVILLE, N.C. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week: BTIG Biotechnology Conference 2022 Date: Monday, August 8, 2022 Location: Hybrid Event at St.

MORRISVILLE, N.C. , July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar , M.D., Liquidia’s new Chief Medical Officer, it has agreed to grant him an employment inducement equity award.